Page 26 - Risk Evaluation News Today

16.06.2023 - Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to add positive data from the Phase 3 VALOR-HCM study to the U.S. Prescribing Information for ...

Washington, D.C. (PRWEB) June 14, 2023 -- The full program, including session details and confirmed speakers for the 7th annual Toxic Substances Control Act

Brixadi (buprenorphine) is approved for patients with moderate to severe OUD who are already taking or have initiated transmucosal buprenorphine.

Providing this treatment for patients with cancer may be a smoother transition for oncology professionals than they might expect.

WHRO Public Media is dedicated to enhancing the lives of the citizens in the communities it serves by responding to their need to be engaged, educated, entertained and enlightened.

-- In CIBMTR Registry Analysis, Tecartus Also Demonstrates 88% Complete Response Rate and 94% Overall Response Rate in Second-and-Third-Line Treatment -- -- Data Highlighted in Oral Presentation at... | June 6, 2023

Brixadi is approved for patients with moderate-to-severe OUD who are already taking or have initiated transmucosal buprenorphine.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA)...

The application is supported by the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival compared to standard regimens CARTITUDE-4 is the... | June 6, 2023